Literature DB >> 7780958

Overexpression of Bcl-XS sensitizes MCF-7 cells to chemotherapy-induced apoptosis.

V N Sumantran1, M W Ealovega, G Nuñez, M F Clarke, M S Wicha.   

Abstract

Resistance to apoptosis plays an important role in tumors that are refractory to chemotherapy. We report that Bcl-XL, which functions like Bcl-2 to inhibit apoptosis, is highly expressed in MCF-7 human breast carcinoma cells. We used Bcl-XS, a dominant negative inhibitor of Bcl-2 and Bcl-XL, to demonstrate the role of these genes in modulating chemotherapy-induced apoptosis. Bcl-XS overexpressed in MCF-7 cells by stable transfection does not affect viability by itself but induces a marked increase in chemosensitivity to VP-16 or taxol. Using an ELISA assay which quantitates DNA damage, we demonstrate that this sensitization is due to apoptosis, suggesting the therapeutic utility of targeting this pathway.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7780958

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

1.  A bcl-xS adenovirus selectively induces apoptosis in transformed cells compared to normal mammary cells.

Authors:  V N Sumantran; D S Lee; K M Woods Ignatoski; S P Ethier; M S Wicha
Journal:  Neoplasia       Date:  2000 May-Jun       Impact factor: 5.715

2.  Mechanisms of resistance to alkylating agents.

Authors:  G Damia; M D'Incalci
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

3.  Regulation of Bcl-xL expression in lung vascular smooth muscle.

Authors:  Yuichiro J Suzuki; Hiroko Nagase; Chi Ming Wong; Shilpashree Vinod Kumar; Vivek Jain; Ah-Mee Park; Regina M Day
Journal:  Am J Respir Cell Mol Biol       Date:  2007-02-01       Impact factor: 6.914

Review 4.  Targeting cancer cell death with a bcl-XS adenovirus.

Authors:  J S Han; G Núñez; M S Wicha; M F Clarke
Journal:  Springer Semin Immunopathol       Date:  1998

5.  Overexpression of bax sensitizes breast cancer MCF-7 cells to cisplatin and etoposide.

Authors:  C Sakakura; E A Sweeney; T Shirahama; Y Igarashi; S Hakomori; H Tsujimoto; T Imanishi; M Ogaki; T Ohyama; J Yamazaki; A Hagiwara; T Yamaguchi; K Sawai; T Takahashi
Journal:  Surg Today       Date:  1997       Impact factor: 2.549

6.  Killing of sarcoma cells by proapoptotic Bcl-X(S): role of the BH3 domain and regulation by Bcl-X(L).

Authors:  R S Mitra; M A Benedict; D Qian; K E Foreman; D Ekhterae; B J Nickoloff; G Nuñez
Journal:  Neoplasia       Date:  2001 Sep-Oct       Impact factor: 5.715

7.  Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin.

Authors:  F Czubayko; A M Schulte; G J Berchem; A Wellstein
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

8.  The BH3 domain of Bcl-x(S) is required for inhibition of the antiapoptotic function of Bcl-x(L).

Authors:  B S Chang; A Kelekar; M H Harris; J E Harlan; S W Fesik; C B Thompson
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

9.  BCNU down-regulates anti-apoptotic proteins bcl-xL and Bcl-2 in association with cell death in oligodendroglioma-derived cells.

Authors:  Richard A Lytle; Zhihong Jiang; Xiao Zheng; Keith M Rich
Journal:  J Neurooncol       Date:  2004-07       Impact factor: 4.130

10.  Emetine regulates the alternative splicing of Bcl-x through a protein phosphatase 1-dependent mechanism.

Authors:  Kritsanapol Boon-Unge; Qingming Yu; Tie Zou; An Zhou; Piyarat Govitrapong; Jianhua Zhou
Journal:  Chem Biol       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.